Zhang is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry, particularly in China.

Zhi Zhang
Latest news
-

LifeArc and the Gates Foundation launches groundbreaking new projects to lower the cost of monoclonal antibody production
-

We must confront this silent pandemic as a global collective
-

PACE announces £6 million funding for antibacterial treatment innovations to fill critical gap in R&D pipeline
